Navigation Links
Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
Date:3/13/2013

te of MACE in the Light Study, the timing of approval for Contrave, the submission of a Contrave application for marketing authorization in Europe and the negotiation of a partnership for the rest-of-world rights to Contrave and Empatic, the expected cash usage for the year 2013, the development of Empatic and the communication with the FDA, the possibility that a cardiovascular outcomes trial will be needed for Empatic, and the commercial potential of Contrave and Empatic. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: Orexigen's ability to conduct the Light Study and the progress and timing thereof; Orexigen's ability to demonstrate in the Light Study that the risk of MACE in overweight and obese subjects treated with Contrave does not adversely affect the product candidate's benefit-risk profile; the potential that earlier clinical trials or analyses (such as the interim analysis) may not be predictive of future results in the Light Study or Phase 3 trials for Empatic; the Special Protocol Assessment (SPA) is not binding on the FDA if public health concerns unrecognized at the time the SPA agreement was entered into become evident, other new scientific concerns regarding product safety or efficacy arise, or if Orexigen fails to comply with the agreed upon trial protocol; the potential for the FDA to not approve Contrave or Empatic; the potential for early termination of the collaboration agreement between Orexigen and Takeda; the costs and time required to complete additional clinical, non-clinical or other requirements prior to any resubmission of an NDA for Contrave or an NDA for Empatic; the therapeutic and commercial value of Contrave or Empatic; Orexigen's ability to maintain sufficient capital; and other ri
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... VeraTag(TM) Assays in Breast ... Cancer, SOUTH ... announced five posters to be,presented at the 30th San Antonio Breast Cancer Symposium ... details for,each embargoed session:, -- Friday, December 14th, 2007, 7.00 am ...
... Biotech today announced that 12,clinical studies of DOXIL(R) ... the 49th annual meeting of the American Society ... on December 8-11,2007., "We are very pleased ... Craig Tendler, M.D., Vice President, Medical Affairs,Oncology/Nephrology, Ortho ...
Cached Medicine Technology:Monogram Announces Posters to be Presented at the 30th San Antonio Breast Cancer Symposium 2Monogram Announces Posters to be Presented at the 30th San Antonio Breast Cancer Symposium 3Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting 2Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting 3Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting 4Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting 5Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting 6Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting 7Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting 8Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting 9
(Date:4/17/2014)... targets that could be used to provide relief ... London made the discovery when researching how pain ... body. , Dr Marzia Malcangio said: "We have ... and our findings could help chemotherapy patients who ... side effect of some chemotherapy drugs (such as ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary ... Paul Kenis in the Institute of Genomic Biology ... Illinois Urbana-Champaign describe their recent work on subcellular ... of cell functions including energy metabolism, signaling, and ... regulating normal cellular behavior, redox status has been ...
(Date:4/17/2014)... a review published in the April issue of ... Feinstein Institute for Medical Research, says it,s time to ... approach to treating sepsis, which kills millions worldwide ... occurs when molecules released into the bloodstream to fight ... Inflammation is necessary for maintaining good health without ...
(Date:4/17/2014)... personnel who served in Iraq and Afghanistan and ... (TBI) were compared to military personnel without TBI ... in measures of overall disability, cognitive function, post-traumatic ... reported in an article in Journal of ... Liebert, Inc., publishers. The article is available free ...
(Date:4/17/2014)... YORK, NY (April 16, 2014) The cause of ... a new study proposes that neurons may be mistaken ... immune system, similar to the way autoimmune diseases like ... the body,s cells. The study was published April 16, ... a new, and likely controversial, idea in Parkinson,s disease; ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Is Parkinson's an autoimmune disease? 2
... much within a generation and nearly 1000 British women are ... issued a warning// that mixtures of chemicals present in day ... of breast cancer. ,Synthetic estrogens have caught the ... to the female sex hormone estrogen. Estrogen which is an ...
... taking the death toll in the capital to 33 Tuesday, ... the mosquito-borne viral disease showing no signs of abating. ... 83 new patients admitted in the city hospitals since Monday. ... 55-year-old Pritam of Faridabad town close to the national capital. ...
... Treatment outcomes vary widely and depend on which state, ... the finding of a new report//. ,The report, ... have a 69 percent lower risk of dying at ... the difference between the best- and worst-performing hospitals has ...
... needs this year according to state and federal officials who ... a shot. ,Annemarie Beardsworth, adult-immunization manager at the ... Rhode Island's public flu clinics, which started on Oct. 2, ... regular shipments. ,Beardsworth said, "Anyone who wants to ...
... United States researchers have explained the recent improvements in the ... slowing// the onset of paralysis. It is observed that people ... in charge of breathing actually stop working. Despite all the ... reasons that cause the disease. ,During the study, ...
... drug funding agency has confirmed that herceptin, a drug ... spite of ongoing criticism// over the decision. The deputy ... drug is highly expensive and funding could not be ... and has been arrived at after complete investigation of ...
Cached Medicine News:Health News:One More Victim Succumbs to Dengue in Delhi 2Health News:Hospital Outcome Linked to its Quality 2
... Injectable was designed to provide the surgeon with ... of surgical complications during cataract and retinal surgery. ... small and medium sized pupils which allows expansion ... iris sphincter during surgery, and allows the pupil ...
... Flow Unit is a flexible, total solution. , ... operating theaters since 1983. A major part of ... extensive experience from all the different areas of ... , ,Kojair Tech Oy is a comprehensive supplier. ...
Provides stable positioning of the knee during surgery....
BRAT 2 Autologous Blood Recovery System gives performance, speed, versatility, and quality processing. , ,The BRAT 2 is now available with on-board Vacuum, programmability, plasma sequestration, Data...
Medicine Products: